{"entity":{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","aka":[],"tldr":"High-dose radioactive MIBG delivers radiation from inside neuroblastoma cells that take up noradrenaline; used for relapsed disease and tested in upfront therapy.","summary":"Response rate ~30-40% in relapsed/refractory MIBG-avid neuroblastoma (NANT, COG studies), with myelosuppression requiring stem-cell support at ≥12 mCi/kg. COG ANBL1531 randomised 131I-MIBG added to induction (primary results pending 2026). Commercial Azedra (for pheochromocytoma) was discontinued in 2024, leaving compounding and academic supply.","status":"established","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Iobenguane","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Iobenguane"}],"tags":[],"related":["i-131"],"indications":["neuroblastoma","neuroblastoma-high-risk","metastatic-ppgl"],"sections":[],"technologies":["mibg-theranostics","radioligand-therapy"],"targets":[],"drugs":[],"companies":["lantheus"],"institutions":[],"pathways":[],"terms":[],"trials":["anbl1531"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"Radioligand therapy (beta, norepinephrine transporter)","mechanism":"Norepinephrine transporter uptake of radio-iodinated benzylguanidine; 131I beta emission (2 mm range).","approvals":[],"mechanismSteps":[],"dosing":{"route":"IV","schedule":"12-18 mCi/kg single or tandem doses with autologous stem-cell support; thyroid blockade with potassium iodide","monitoring":"Radiation isolation, counts, thyroid function, secondary malignancy"},"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/i131-mibg/","neighbours":{"isotope":[{"id":"i-123","kind":"isotope","name":"Iodine-123","route":"/isotopes/i-123/"},{"id":"i-131","kind":"isotope","name":"Iodine-131","route":"/isotopes/i-131/"}],"indication":[{"id":"neuroblastoma-high-risk","kind":"indication","name":"High-risk neuroblastoma","route":"/indications/neuroblastoma-high-risk/"},{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/"},{"id":"neuroblastoma","kind":"indication","name":"Neuroblastoma (paediatric)","route":"/indications/neuroblastoma/"},{"id":"pheochromocytoma-paraganglioma","kind":"indication","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/indications/pheochromocytoma-paraganglioma/"}],"technology":[{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"company":[{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/"}],"trial":[{"id":"anbl1531","kind":"trial","name":"COG ANBL1531","route":"/trials/anbl1531/"}],"term":[{"id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/"}],"person":[{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/"}],"paper":[{"id":"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019","kind":"paper","name":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma","route":"/key-papers/paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019/"}],"drug":[{"id":"i-123-mibg","kind":"drug","name":"Iobenguane I-123","route":"/drugs/i-123-mibg/"},{"id":"i-123-mibg-cardiac","kind":"drug","name":"Iobenguane I-123 (cardiac use)","route":"/drugs/i-123-mibg-cardiac/"}],"target":[{"id":"norepinephrine-transporter","kind":"target","name":"Norepinephrine transporter (NET)","route":"/targets/norepinephrine-transporter/"}]}}